Does T50.995D require prior authorization?

No, T50.995D does not require prior authorization (high confidence). Covered without prior authorization.

Backwork Sign up free

`T50.995D`, Adverse effect of other drugs, medicaments and biological substances, subsequent encounter

ICD-10-CM

Prior Authorization

No Prior Auth Required

Covered without prior authorization (high confidence)

Documentation Required

Medical record documentation must demonstrate that the patient cannot tolerate oral bisphosphonates or that oral bisphosphonates are medically contraindicated (including documentation of severe esophagitis when applicable).
If inability to tolerate oral ibandronate is claimed, include appropriate intolerance/interaction codes (T50.995A-T50.995S, Y63.8, Z91.89, or Z92.89) in the documentation and claims as applicable.
For hypercalcemia of malignancy (E83.52), document the clinical rationale for ibandronate use and the specific related malignancy in the patient record.

Key Coverage Criteria

Intravenous ibandronate sodium is reasonable and necessary only for patients for whom bisphosphonate therapy (including oral ibandronate) is medically indicated and who cannot tolerate oral therapy or have a medical contraindication to oral bisphosphonates.
Use for osteoporosis (including senile or other osteoporosis) is covered when oral bisphosphonate therapy is indicated but cannot be used due to intolerance or contraindication.
Ibandronate sodium may be used for management of hypercalcemia of malignancy when the medical record documents the rationale for use and the related malignancy.
Ibandronate sodium may be used for osteoporosis that is a complication of transplant when the claim includes the related complication-of-transplant code and documentation of inability to tolerate oral bisphosphonates.
Paclitaxel administered intravenously is covered for antineoplastic (cancer) indications when used in accordance with the FDA-approved labeling.
Off-label uses of paclitaxel are covered when supported by recognized compendia (e.g., NCCN, AHFS, Clinical Pharmacology, Lexi-Drugs, Micromedex) and dosing/frequency follow those compendia.

20 Active Policies

CGS-J15-L37598, Cystatin C Measurement

J15

CGS-J15-L40325, Allergy Diagnostic Testing

J15

CGS-J18-L37598, Cystatin C Measurement

J18

CGS-J18-L40325, Allergy Diagnostic Testing

J18

NGS-J6-L33394, Drugs and Biologicals, Coverage of, for Label and Off-Label Uses

NGS-J6-L40329, Allergy Diagnostic Testing

NGS-J6-L33591, RAST Type Tests

A52421, Billing and Coding: Ibandronate Sodium

A56844, Billing and Coding: RAST Type Tests

A52450, Billing and Coding: Paclitaxel (e.g., Taxol/Abraxane )

FIRST_COAST-L33261, Allergy Testing

A57678, Billing and Coding: Allergen Immunotherapy

A57531, Billing and Coding: Allergy Testing

FIRST_COAST-L37800, Allergen Immunotherapy

FIRST_COAST-L33967, Vitamin B<sub>12</sub> Injections

NOVITAS-JH-L36240, Allergen Immunotherapy

NOVITAS-JH-L35006, Controlled Substance Monitoring and Drugs of Abuse Testing

NOVITAS-JH-L35049, Monitored Anesthesia Care

NOVITAS-JH-L36241, Allergy Testing

NGS-JK-L33591, RAST Type Tests

`T50.995D`, Adverse effect of other drugs, medicaments and biological substances, subsequent encounter

Prior Authorization

Documentation Required

Key Coverage Criteria

20 Active Policies

Related Codes

Have a follow-up question?

T50.995D, Adverse effect of other drugs, medicaments and biological substances, subsequent encounter

Prior Authorization

Documentation Required

Key Coverage Criteria

20 Active Policies

Related Codes

Have a follow-up question?

`T50.995D`, Adverse effect of other drugs, medicaments and biological substances, subsequent encounter